Cardoso, HJVaz, CVCorreia, SaraFigueira, Marília IMarques, RicardoBaptista, CláudioSocorro, Sílvia2019-12-042019-12-042015-06-15http://hdl.handle.net/10400.6/7665Imatinib mesylate is a chemotherapeutic drug that inhibits the tyrosine kinase activity of c-KIT and has been successfully used to treat leukemias and some solid tumors. However, its application for treatment of hormone-refractory prostate cancer (HRPC) has shown modest effectiveness and did not follow the outcomes in cultured cells or animal models. Moreover, the molecular pathways by which imatinib induces cytotoxicity in prostate cancer cells are poorly characterized.engc-KITDU14Hormone-refractory prostate cancerImatinibPC3Prostate cancer cellsjournal article10.1002/pros.22976